Medical Advocates
Indinavir (Crixivan)
 
Pediatric Data

General Reports
 Pharmacokinetics
 Monotherapy
 Combination Therapy
 Switching Drugs

 
Indinavir Main Page Main New/Newsworthy  Home Page      
Last Update:  August 21, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
   
General Reports
       

        Journal Papers, Abstracts, and Commentaries

 
Indinavir-Loaded pH-Sensitive Microparticles for Taste Masking: Toward Extemporaneous
Pediatric Anti-HIV/AIDS Liquid Formulations with Improved Patient Compliance.
Chiappetta DA, Carcaboso AM, Bregni C, et al 
AAPS PharmSciTech. 2009 Jan 6.
 Abstract

Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
Fraaij PL, Bergshoeff AS, Van Rossum AM ,et al 
J Antimicrob Chemother. 2003 Oct;52(4):727-30.
Abstract
 
 
Pharmacokinetics
 

          Journal Papers, Abstracts, and Commentaries

 
Pharmacokinetic Study of the Variability of Indinavir Drug Levels when Boosted with Ritonavir
in HIV-Infected Children.
Curras V, Höcht C, Mangano A  
Pharmacology. 2008 Dec 4;83(1):59-66
 Abstract
 
Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human
Immunodeficiency Virus Type 1-Infected Children.
 Bergshoeff AS, Fraaij PL, Van Rossum AM, et al 
Antimicrob Agents Chemother. 2004 May;48(5):1904-1907.
 Abstract

FULL-TEXT ARTICLE
 Indinavir pharmacokinetics and pharmacodynamics in children with human
immunodeficiency virus infection.
Gatti G, Vigano' A, Sala N, Vella S, et al.
Antimicrob Agents Chemother 2000 Mar;44(3):752-755
 Paper
   
  FULL-TEXT ARTICLE
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus
type 1-infected children.
Burger DM, van Rossum AMC, Hugen PWH, et al
 Antimicrobial Agents and Chemotherapy 2001; 45:701-705. 
Paper
   
  Long-term virologic and immunologic responses in human immunodeficiency virus type
1-infected children treated with indinavir, zidovudine and lamivudine.
Jankelevich S, Mueller BU,Mackall CL, et al
Journal of Infectious Disease 2001; 183:1116-1120. 
 Abstract
Monotherapy
 

             Journal Papers, Abstracts, and Commentaries

  A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
Mueller BU, Sleasman J, Nelson RP et al
Pediatrics 1998; 102 (1 Pt 1): 101-109.
 Abstract
Combination Therapy
 

IND/RTV

             Journal Papers, Abstracts, and Commentaries

 
Indinavir/Low-dose Ritonavir Containing HAART in HIV-1 Infected Children has Potent
Antiretroviral Activity, but is Associated with Side Effects and Frequent Discontinuation
of Treatment.
 Fraaij PL, Verweel G, van Rossum AM, et al
Infection. 2007 Jun;35(3):186-9.
 Abstract
 
Efficacy and Plasma Concentrations of Indinavir when Boosted with Ritonavir in HIV-Infected
Thai Children
 Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K.
Pediatr Infect Dis J. 2007 Jan;26(1):86-88
 Abstract

Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human
Immunodeficiency Virus Type 1-Infected Children.
 Bergshoeff AS, Fraaij PL, Van Rossum AM, et al 
Antimicrob Agents Chemother. 2004 May;48(5):1904-1907.
 Abstract

IND/STV/DDI

             Journal Papers, Abstracts, and Commentaries

  A pilot study of combination therapy with indinavir, stavudine (d4T), |and didanosine
(ddI) in children infected with the human immunodeficiency virus.
Journal of Pediatrics1 998; 132(3 Pt 1): 543-546.
Abstract
   
  FULL-TEXT ARTICLE
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human
immunodeficiency virus-infected children receiving combination therapy.
Fletcher CV, Brundage RC, Remmel RP et al
Antimicrobial Agents and Chemotherapy 2000; 44(4): 1029-1034.
 Paper

IND/STV/3TC

           Journal Papers, Abstracts, and Commentaries

  Clinical and virologic response to combination treatment with indinavir, zidovudine,
and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter
study in The Netherlands.
van Rossum AMC, Niesters HGM, Geelen SPM, et al.
Journal of Pediatrics 2000; 136:780-788.  
Abstract
   
  Clinical and immuno-virological characterization of the efficacy of stavudine,
lamivudine and indinavir in human immunodeficiency virus infection.
Vigano A, Dally L, Bricalli D, et al.
Journal of Pediatrics 1999; 135(6): 675-82.
Abstract

IND/ZDV/3TC

         Journal Papers, Abstracts, and Commentaries

  Long-term virologic and immunologic responses in human immunodeficiency virus
type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Jankelevich S, Mueller BU, Mackall CL,
Infect Dis. 2001 Apr 1;183(7):1116-20.
 Abstract

Multiple Combinations

         Journal Papers, Abstracts, and Commentaries

  Comparison of two antiretroviral triple combinations including the rotease inhibitor
 indinavir in children infected with human immunodeficiency virus.
Wintergerst U, Hoffmann F, Solder B, et al.
Pediatric infectious Disease Journal 1998; 17:495-499. 
Abstract
Adverse Events
 

             Journal Papers, Abstracts, and Commentaries

  Obstructive uropathy in a HIV+ infant under indinavir treatment.
Serrano-Durbá A, Vivancos S, Berbel O, et al
 J Pediatr Urol. 2007 Dec;3(6):512-3.
 Abstract
Switching Drugs
 

             Journal Papers, Abstracts, and Commentaries

  Switch from Ritonavir to Indinavir in Combination Therapy for HIV-1-Infected Children.
 Pelton SI, Stanley K, Yogev R, et al
Clin Infect Dis. 2005 Apr 15;40(8):1181-7
 Abstract

Indinavir Main Page Main New/Newsworthy  Home Page      

Indinavir Pediatric Data